| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Clinical Investigation |
1 Center for Radiopharmaceutical Science of ETH, PSI, and USZ, Department of Chemistry and Applied Biosciences of ETH, Zurich, Switzerland; 2 PET Center, Division of Nuclear Medicine, University of Zurich, Zurich, Switzerland; 3 Division of Psychiatric Research, University of Zurich, Zurich, Switzerland; and 4 Novartis Institutes for Biomedical Research Basel, Novartis Pharma AG, Basel, Switzerland
Correspondence: For correspondence or reprints contact: Simon M. Ametamey, PhD, Center for Radiopharmaceutical Science of ETH, PSI, and USZ, ETH-Hönggerberg, D-CHAB IPW HCI H427, Wolfgang-Pauli-Strasse 10, CH-8093 Zurich, Switzerland. E-mail: simon.ametamey{at}pharma.ethz.ch
3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-O-11C-methyl-oxime (11C-ABP688), a noncompetitive and highly selective antagonist for the metabotropic glutamate receptor subtype 5 (mGluR5), was evaluated for its potential as a PET agent. Methods: Six healthy male volunteers (mean age, 25 y; range, 21–33 y) were studied. Brain perfusion (15O-H2O) was measured immediately before each 11C-ABP688 PET scan. For anatomic coregistration, T1-weighted MRI was performed on each subject. Arterial blood samples for the determination of the arterial input curve were obtained at predefined time points, and 11C-ABP688 uptake was assessed quantitatively using a 2-tissue-compartment model. Results: An initial rapid uptake of radioactivity followed by a gradual clearance from all examined brain regions was observed. Relatively high radioactivity concentrations were observed in mGluR5-rich brain regions such as the anterior cingulate, medial temporal lobe, amygdala, caudate, and putamen, whereas radioactivity uptake in the cerebellum and white matter, regions known to contain low densities of mGluR5, was low. Specific distribution volume as an outcome measure of mGluR5 density in the various brain regions ranged from 5.45 ± 1.47 (anterior cingulate) to 1.91 ± 0.32 (cerebellum), and the rank order of the corresponding specific distribution volumes of 11C-ABP688 in cortical regions was temporal > frontal > occipital > parietal. The metabolism of 11C-ABP688 in plasma was rapid; at 60 min after injection, 25% ± 0.03% of radioactivity measured in the plasma of healthy volunteers was intact parent compound. Conclusion: The results of these studies indicate that 11C-ABP688 has suitable characteristics and is a promising PET ligand for imaging mGluR5 distribution in humans. Furthermore, it could be of great value for the selection of appropriate doses of clinically relevant candidate drugs that bind to mGluR5 and for PET studies of patients with psychiatric and neurologic disorders.
Key Words: metabotropic glutamate receptor subtype 5 • 11C-ABP688 • positron emission tomography • specific distribution volume
COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.
Related articles in JNM:
This article has been cited by other articles:
|
|
 |
|
  A. K. Brown, Y. Kimura, S. S. Zoghbi, F. G. Simeon, J.-S. Liow, W. C. Kreisl, A. Taku, M. Fujita, V. W. Pike, and R. B. Innis Metabotropic Glutamate Subtype 5 Receptors Are Quantified in the Human Brain with a Novel Radioligand for PET J. Nucl. Med., December 1, 2008; 49(12): 2042 - 2048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Treyer, J. Streffer, M. T. Wyss, A. Bettio, S. M. Ametamey, U. Fischer, M. Schmidt, F. Gasparini, C. Hock, and A. Buck Evaluation of the Metabotropic Glutamate Receptor Subtype 5 Using PET and 11C-ABP688: Assessment of Methods J. Nucl. Med., July 1, 2007; 48(7): 1207 - 1215. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
